BridgeBio Pharma Inc’s recent filing unveils that its Director ANDREW W LO acquired Company’s shares for reported $2.71 million on Nov 17 ’25. In the deal valued at $66.67 per share,40,599 shares were bought.
Then, RANDAL SCOTT bought 10,000 shares, generating $663,900 in total proceeds.
Before that, THOMAS TRIMARCHI bought 16,934 shares. BridgeBio Pharma Inc shares valued at $1,125,403 were divested by the Officer at a price of $66.46 per share.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Monday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 0.77% to $66.9. Over the last five days, the stock has gained 6.51%. BridgeBio Pharma Inc shares have risen nearly 169.87% since the year began. Nevertheless, the stocks have risen 143.80% over the past one year. While a 52-week high of $69.48 was reached on 10/29/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 65.70, which if violated will result in even more drops to 64.51. On the upside, there is a resistance level at 67.79. A further resistance level may holdings at 68.69.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-10-31, growing by 2.08 million shares to a total of 19.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 17.49 million shares. There was a rise of 10.63%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
